These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 37863669)

  • 1. Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants.
    Honda-Okubo Y; Bowen R; Barker M; Bielefeldt-Ohmann H; Petrovsky N
    Vaccine; 2023 Nov; 41(48):7116-7128. PubMed ID: 37863669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters.
    Li L; Honda-Okubo Y; Baldwin J; Bowen R; Bielefeldt-Ohmann H; Petrovsky N
    Vaccine; 2022 May; 40(23):3182-3192. PubMed ID: 35465982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine.
    Petrovsky N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2363016. PubMed ID: 38839044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge.
    Honda-Okubo Y; Li L; André G; Leong KH; Howerth EW; Bebin-Blackwell AG; Ross TM; Petrovsky N
    Vaccine; 2023 Jul; 41(32):4710-4718. PubMed ID: 37355452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
    Pal R; Ferrari MG; Honda-Okubo Y; Wattay L; Caple J; Navarrete J; Andersen H; Petrovsky N
    Vaccine; 2024 Feb; 42(5):1122-1135. PubMed ID: 38262808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ability of SpikoGen®, an Advax-CpG adjuvanted recombinant spike protein vaccine, to induce cross-neutralising antibodies against SARS-CoV-2 variants.
    Honda-Okubo Y; Antipov A; Andre G; Barati S; Kafi H; Petrovsky N
    Immunology; 2023 Oct; 170(2):193-201. PubMed ID: 37199229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a SARS-CoV-2 spike protein ectodomain subunit vaccine with a squalene emulsion adjuvant in rodents and rhesus macaques.
    Solomadin M; Tabynov K; Petrovsky N; Tabynov K
    Hum Vaccin Immunother; 2023 Aug; 19(2):2258571. PubMed ID: 37880990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developmental and reproductive safety of Advax-CpG55.2™ adjuvanted COVID-19 and influenza vaccines in mice.
    Sakala IG; Honda-Okubo Y; Petrovsky N
    Vaccine; 2023 Sep; 41(41):6093-6104. PubMed ID: 37659896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters.
    Hsieh M-S; Hsu C-W; Liao H-C; Lin C-L; Chiang C-Y; Chen M-Y; Liu S-J; Liao C-L; Chen H-W
    J Virol; 2024 Feb; 98(2):e0154623. PubMed ID: 38299865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.
    González-Domínguez I; Martínez JL; Slamanig S; Lemus N; Liu Y; Lai TY; Carreño JM; Singh G; Singh G; Schotsaert M; Mena I; McCroskery S; Coughlan L; Krammer F; García-Sastre A; Palese P; Sun W
    Microbiol Spectr; 2022 Jun; 10(3):e0153822. PubMed ID: 35658571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
    Deliyannis G; Gherardin NA; Wong CY; Grimley SL; Cooney JP; Redmond SJ; Ellenberg P; Davidson KC; Mordant FL; Smith T; Gillard M; Lopez E; McAuley J; Tan CW; Wang JJ; Zeng W; Littlejohn M; Zhou R; Fuk-Woo Chan J; Chen ZW; Hartwig AE; Bowen R; Mackenzie JM; Vincan E; Torresi J; Kedzierska K; Pouton CW; Gordon TP; Wang LF; Kent SJ; Wheatley AK; Lewin SR; Subbarao K; Chung AW; Pellegrini M; Munro T; Nolan T; Rockman S; Jackson DC; Purcell DFJ; Godfrey DI
    EBioMedicine; 2023 Jun; 92():104574. PubMed ID: 37148585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
    Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X
    J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern.
    Xu J; Zhang Y; Qu P; Shamseldin MM; Yoo SJ; Misny J; Thongpan I; Kc M; Hall JM; Evans JP; Eltobgy M; Lu M; Ye C; Chamblee M; Liang X; Martinez-Sobrido L; Amer AO; Yount JS; Boyaka PN; Peeples ME; Liu SL; Dubey P; Li J
    Proc Natl Acad Sci U S A; 2023 Oct; 120(41):e2220403120. PubMed ID: 37796985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
    J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P.
    Kuo TY; Lien CE; Lin YJ; Lin MY; Wu CC; Tang WH; Campbell JD; Traquina P; Chuang YS; Liu LT; Cheng J; Chen C
    J Infect Dis; 2022 Nov; 226(9):1562-1567. PubMed ID: 35451470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters.
    de Moor WRJ; Williamson AL; Schäfer G; Douglass N; Gers S; Sutherland AD; Blumenthal MJ; Margolin E; Shaw ML; Preiser W; Chapman R
    Viruses; 2023 Jun; 15(7):. PubMed ID: 37515096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster.
    Jitender ; Vikram Kumar B; Singh S; Verma G; Kumar R; Mishra PM; Kumar S; Nagaraj SK; Nag J; Joy CM; Nikam B; Singh D; Pooja ; Kalidas N; Singh S; Mumtaz ; Bhardwaj AK; Mankotia DS; Ringe RP; Gupta N; Tripathi S; Mishra RPN
    Vaccine; 2024 Aug; 42(20):126099. PubMed ID: 38981743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial.
    Tabarsi P; Anjidani N; Shahpari R; Roshanzamir K; Fallah N; Andre G; Petrovsky N; Barati S
    Immunology; 2022 Nov; 167(3):340-353. PubMed ID: 35758850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.